In May, the House of Representatives launched its 21st
Century Cures Initiative aimed at engaging stakeholders to develop policies
that will help bring new drugs to market. In response to a request for input,
IDSA highlighted the need for new incentives and regulatory changes to spur
R&D for new antibiotics and rapid diagnostics as well as public health
interventions to slow the rise of resistance.
One dozen pharmaceutical companies signed a letter to Congress in support of the LPAD approval pathway (as proposed by IDSA) for antibacterials to treat serious or life-threatening infections with few, if any, satisfactory therapeutic options.
1300 Wilson Boulevard Suite 300 Arlington, VA 22209 | Phone: (703) 299-0200 | Fax: (703) 299-0204
| HIVMA | Contact Us
© Copyright IDSA 2016 Infectious Diseases Society of America